肿瘤药学2016，Vol.6Issue(1)：21-25,5.DOI:10.3969/j.issn.2095-1264.2016.01.05
胶质瘤中MGMT、BRAF和EGFR的变化及其治疗的研究进展
Research Progress in Changes of MGMT, BRAF and EGFR in Gliomas and their Correlation with Treatment of Gliomas
高翔 1罗林1
作者信息
- 1. 昆明医科大学第三附属医院神经外科，云南昆明，650118
- 折叠
摘要
Abstract
With the development and progress of molecular biology techniques, the research of molecular markers for diagnosis, differential diagnosis and targeted drug therapy of gliomas has also made a great progress. The drugs developed on the base of molecular markers like O6-methylguanine-DNA methyltransferase (MGMT), murine sarcoma viral oncogenic homolog B1 (BRAF) gene and epidermal growth factor receptor (EGFR) also achieved some results in the treatment of glioma. Different types of gliomas have different pathogenesis, and the drugs based on different molecular markers provided a new re-search direction for individualized treatment and combination therapy of glioma patients. In this paper, the changes of EGFR, BRAF and MGMT in gliomas and the progress of glioma therapy were reviewed.关键词
胶质瘤/分子标志物/O6-甲基鸟嘌呤-DNA-甲基转移酶/鼠类肉瘤滤过性毒菌致癌同源体B1/表皮生长因子受体Key words
Glioma/Molecularmarkers/MGMT/BRAF/EGFR分类
医药卫生引用本文复制引用
高翔,罗林..胶质瘤中MGMT、BRAF和EGFR的变化及其治疗的研究进展[J].肿瘤药学,2016,6(1):21-25,5.
